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Abstract 
Background: Pulmonary vascular resistance (PVR) is an important parameter in the 
management of patients with chronic thromboembolic pulmonary hypertension (CTEPH), 
and numerous noninvasive methods for PVR prediction have been proposed. However, a 
systematic evaluation of the methods that are specific for CTEPH has not been conducted. 
We compared a variety of echocardiography-derived prediction indices with direct right heart 
catheterization (RHC) to identify the most reliable noninvasive indicator of PVR in patients 
with CTEPH. 
Patients and methods: Echocardiography and RHC were performed sequentially in 40 
patients (mean age: 62.4±11.4 years; 30 females) with CTEPH. We measured the peak flow 
velocity of tricuspid regurgitation (TRV), tricuspid regurgitation pressure gradient (TRPG), 
right ventricular outflow tract (RVOT) time-velocity integral (TVIRVOT), left ventricular 
outflow tract (LVOT) time-velocity integral (TVILVOT), cardiac output at RVOT (CORVOT), 
and the LVOT (COLVOT) using echocardiography. The parameters TRV/TVIRVOT, 
TRV/TVILVOT, TRV/CORVOT, TRV/COLVOT, TRPG/TVIRVOT, TRPG/TVILVOT, TRPG/CORVOT, 
and TRPG/COLVOT were then calculated to predict the PVR. Finally, correlations between 
these echocardiographic predictors of PVR and the PVR data obtained from RHC (PVRRHC) 
were assessed. 
Results: The mean pulmonary arterial pressure and PVRRHC were 32.1±11.4 mmHg and 
5.4±2.9 Wood units, respectively. TRV/TVIRVOT, TRV/TVILVOT, TRV/COLVOT, 
TRPG/TVIRVOT, TRPG/TVILVOT, TRPG/CORVOT, and TRPG/COLVOT were all significantly 
correlated with the PVRRHC, and TRPG/COLVOT was the most strongly correlated with the 
PVRRHC (r = 0.807, p < 0.001). 
Conclusions: Echocardiographic measurement of TRPG/COLVOT is a reliable noninvasive 
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predictor of PVR in CTEPH patients. 
Keywords 
pulmonary vascular resistance, chronic thromboembolic pulmonary hypertension, 
echocardiography, invasive  
4 
 
1. Introduction 
Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by 
nonresolving thromboembolisms of the pulmonary arteries and pulmonary vascular 
remodeling, which results in right heart failure unless treatment is effective [1]. 
Hemodynamic evaluation is important in the management of CTEPH; therefore, pulmonary 
vascular resistance (PVR) and the pulmonary arterial pressure (PAP) must be accurately 
assessed. PVR is a strong predictor of reduced survival in medically treated patients, and 
higher PVR is associated with increased mortality following pulmonary endarterectomy 
(PEA) [2-4].  
Although right heart catheterization (RHC) is the gold standard for assessing 
pulmonary hemodynamics, it is invasive and costly. Therefore, noninvasive methods for 
predicting PVR are desirable, and many studies have assessed the use of echocardiography 
for this purpose [5-13]. The peak flow velocity of tricuspid regurgitation (TRV) and the right 
ventricular outflow tract (RVOT) time-velocity integral (TVIRVOT) are most often used for 
this purpose. For example, Abbas et al. reported that using the ratio of TRV/TVIRVOT was a 
reliable method for identifying patients with elevated PVR [10], and that the ratio of 
(TRV)2/TVIRVOT provided an even better noninvasive estimate of PVR [9]. The influence of 
the heart rate (HR) could be neglected, and Haddad et al. reported that systolic PAP 
(sPAP)/(HR × TVIRVOT) provided clinically useful estimations of PVR in pulmonary arterial 
hypertension (PAH) [11]. However, anatomical modifications of right ventricular structures in 
patients with severe pulmonary hypertension (PH) may make it difficult to measure TVIRVOT 
accurately [7]. Hence, the left ventricular outflow tract (LVOT) time-velocity integral 
(TVILVOT) may be easier to measure in these patients. Indeed, the TVILVOT and the cardiac 
output (CO) at the LVOT (COLVOT) have also been used to estimate PVR [7]. 
There is currently no definitive method for the non-invasive estimation of PVR, 
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possibly because previous comparative evaluations included subjects with multiple PH 
etiologies. Moreover, no systematic evaluations of echocardiographic PVR estimates have 
been conducted specifically for CTEPH patients. This study aimed to identify the most 
reliable noninvasive indicator of PVR in patients with CTEPH by comparing a variety of 
echocardiography-derived prediction indices with the PVR data obtained from RHC 
(PVRRHC).  
2. Patients and methods 
2.1 Study population 
This study was a single-center retrospective investigation of consecutive patients 
with a high clinical suspicion of CTEPH who underwent echocardiography and RHC from 
September 2012 to October 2014. This study was approved by the ethics committee of Chiba 
University (Approval date: June 1, 2009; Approval number: 826), and written informed 
consent was obtained from each patient before echocardiography and RHC. Patients with 
suspected CTEPH complicated by left heart disease such as ischemic heart disease or 
cardiomyopathy, or moderate or severe valvular disease of the aortic and mitral valves, 
intracardiac shunts, or patients who underwent PEA within 1 year of the study were excluded 
from the study. Patients complicated with severe tricuspid regurgitation (TR) were also 
excluded, because severe TR reduces the accuracy of the CO calculation using the 
thermodilution method. We defined severe TR as a regurgitation jet area that was more than 
two-thirds of the maximum right atrial area visible on color Doppler echocardiography in the 
apical view [14]. 
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2.2 Echocardiography 
Within 2 days of RHC, Doppler echocardiography using an Aplio™ 300 ultrasound 
(Toshiba Medical, Tochigi, Japan) with a PST-25BT transducer (2.5 MHz) was performed on 
all of the patients while they held their breaths at the end of expiration. The recordings were 
obtained from the left parasternal long axis, left parasternal short axis, apical four-chamber, 
and the apical five-chamber views. All of the results were the averages of three 
measurements, and the analyses were performed without knowledge of the patients’ clinical 
statuses. No changes were made to the medication and oxygen therapy between RHC and 
echocardiography. The TRV was obtained using continuous wave Doppler from the apical 
four-chamber, parasternal, and subcostal views, and the highest peak value was recorded. The 
tricuspid regurgitation pressure gradient (TRPG) was determined from the velocity using a 
simplified Bernoulli equation. 
The TVIRVOT was determined from digitized Doppler signals. We traced the 
black/white interface of the flow profile from time × velocity traces (Fig. 1A) that were 
generated by positioning a pulsed wave Doppler sample volume in the range from just above 
to 1 cm distal to the pulmonary valve, which was the position from which we could most 
clearly visualize the RVOT in the parasternal short-axis view. The RVOT diameter was 
measured at the pulmonic annulus between the inner edges, utilizing zoom images from the 
short-axis view (Fig. 1A, B). Likewise, the TVILVOT was determined by placing a pulsed 
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wave Doppler sample volume in the LVOT in the range from just above to 1 cm distal to the 
aortic valve in the apical five-chamber view. The LVOT diameter was measured at the aortic 
annulus between its inner edges, utilizing zoom images from the apical five-chamber view 
and the parasternal long-axis view (Fig. 1C, B). The CO at the RVOT (CORVOT) was 
calculated using the HR, RVOT diameter, and the TVIRVOT. Assuming a circular shape, the 
cross-sectional area of the RVOT was calculated as follows: 3.14 × (RVOT diameter/2)2. The 
stroke volume was then calculated as the cross-sectional area of the RVOT × TVIRVOT, which 
was then multiplied by the HR to obtain the CORVOT. The CORVOT was calculated as follows: 
3.14 × (RVOT diameter/2)2 × TVIRVOT × HR [15]. The CO at the LVOT (COLVOT) was 
similarly calculated using the HR, LVOT diameter, and the TVILVOT as follows: 3.14 × 
(LVOT diameter/2)2 × TVILVOT × HR [16]. Then, the TRV/TVIRVOT, TRV/TVILVOT, 
TRV/CORVOT, TRV/COLVOT, TRPG/TVIRVOT, TRPG/TVILVOT, TRPG/CORVOT, and 
TRPG/COLVOT were calculated to predict the PVR.  
2.3 Right heart catheterization  
A 7.5-French Swan-Ganz thermodilution catheter (Edwards LifeSciences, Irvine, 
California, USA) was positioned via a jugular approach. At end-expiration, pressure 
measurements from the right atrium, right ventricle, and main pulmonary artery, as well as 
the pulmonary arterial wedge pressure (PAWP) were recorded. The zero point was defined as 
mid-thoracic. The CO was determined using the thermodilution method by averaging at least 
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three measurements. The PVRRHC was calculated as: (mean PAP [mPAP] − PAWP)/CO in 
Wood units (WU). Possible left-to-right shunting was excluded by oximetry.  
2.4 Statistical analyses 
All of the results are expressed as the means ± standard deviations unless otherwise 
indicated. Spearman’s correlation was used to assess the correlations between the PVRRHC 
and the echocardiography-derived estimates, namely, TRV/TVIRVOT, TRV/TVILVOT, 
TRV/CORVOT, TRV/COLVOT, TRPG/TVIRVOT, TRPG/TVILVOT, TRPG/CORVOT, 
TRPG/COLVOT, and PVRRHC. Finally, a Bland-Altman analysis was performed to determine 
the limits of the agreements between the PVR predicted by echocardiography and that 
measured by RHC. A P value of <0.05 was considered statistically significant. All of the 
statistical analyses were performed using JMP 9.0 software (SAS Institute, Cary, North 
Carolina, USA).  
3. Results 
The study group comprised 40 consecutive patients (mean age: 62.4±11.4 years; 30 
females) with CTEPH confirmed by RHC and pulmonary angiography. Tables 1, 2, and 3 
summarize the subjects’ baseline clinical characteristics, hemodynamic data, and 
echocardiographic parameters, respectively.  
Table 4 presents the correlations between PVRRHC and the echocardiographic 
predictors, namely, TRV/TVIRVOT, TRV/TVILVOT, TRV/CORVOT, TRV/COLVOT, 
TRPG/TVIRVOT, TRPG/TVILVOT, TRPG/CORVOT, and TRPG/COLVOT. All of the predictors 
with the exception of TRV/CORVOT were significantly correlated with PVRRHC, and the 
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strongest correlation was between TRPG/COLVOT and PVRRHC (r = 0.807, p < 0.001). 
Figure 2 shows the linear regression plots of PVRRHC versus TRPG/CORVOT and 
TRPG/COLVOT for the 40 patients. The derived linear regression equation from the 
TRPG/COLVOT (PVRECHO) was as follows: PVRECHO = 1.3 + 0.3 × (TRPG/COLVOT). Figure 3 
shows the Bland-Altman analysis used to evaluate the level of agreement between PVRECHO 
and PVRRHC across the patient sample. This analysis revealed a mean difference of −0.3 WU 
between the methods, with limits of agreement from −4.0 to 3.3 WU. 
4. Discussion 
In the present study, TRPG/COLVOT was the echocardiographic parameter that most 
strongly correlated with the PVRRHC, although TRV/TVIRVOT, TRV/TVILVOT, TRV/COLVOT, 
TRPG/TVIRVOT, TRPG/TVILVOT, TRPG/CORVOT, and TRPG/COLVOT were also significantly 
correlated with the PVRRHC. To the best of our knowledge, this is the first study to identify 
TRPG/COLVOT as a reliable predictor of PVR through the comparative analysis of 
echocardiographic predictors of PVRRHC in CTEPH patients.  
Numerous formulas have been developed to predict PVR by echocardiography [5-
13], of which TRV/TVIRVOT is the most widely used. In the PVR equation used in RHC, the 
numerator is (mPAP – PAWP), and the denominator is CO. However, in echocardiography, 
the right ventricular stroke volume is calculated as the RVOT cross-sectional area × TVIRVOT, 
where the TVIRVOT may reflect the stroke volume of the right ventricle. The numerator 
contains the pressure information, whereas the denominator contains the HR and the stroke 
volume information. Although TRV/TVIRVOT has an excellent correlation with PVRRHC [10], 
it does not include an HR component and fails to consider the variation in TVIRVOT caused by 
right ventricular and pulmonary artery dilatation. In addition, the TRPG reflects sPAP, 
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whereas the TRV only reflects flow velocity. Therefore, TRV/TVIRVOT may be insufficient for 
the prediction of PVRRHC. Furthermore, Xie et al. reported that the degree of correlation 
between TRV/TVIRVOT and PVR could vary according to the PH severity and its etiologies 
[12]. Rajagopalan et al. reported that the correlation coefficient between TRV/TVIRVOT and 
PVR was higher in patients with relatively low PVR (<8 WU) [17], so this method may be 
unreliable for severe PH cases. We speculate that the PVRRHC can be more accurately 
estimated using TRV/TVIRVOT if the numerator is replaced by the TRPG (from the TRV) and 
the denominator is replaced by the CORVOT or COLVOT (from the TVIRVOT), because this 
would more closely reflect the PVRRHC equation. 
TRPG/COLVOT (r = 0.807) was a better predictor of PVR than either TRPG/TVIRVOT 
(r = 0.657) or TRPG/CORVOT (r = 0.597). Although previous studies have reported good 
correlations between PVRRHC and the prediction equation using the TRVRVOT [7-12, 17], 
anatomical variations in the right heart structures may interfere with the measurements of the 
TVIRVOT. In addition, a markedly dilated RVOT or pulmonary artery may skew the spatial 
velocity distribution such that the velocity sampled in one region may not reflect the average 
velocity or actual stroke volume [13, 18]. In other words, the TVIRVOT value will change with 
a slight shift in the measurement site. Indeed, Mauritz et al. reported the limited accuracy of 
stroke volume assessments from the pulmonary artery flow, whereas stroke volume 
assessments from the aortic flow were acceptable in patients with PAH [19]. In the current 
study, the prediction of PVR using the CORVOT was less accurate than that using the TVIRVOT. 
The reasons for this are uncertain, but it may reflect the inclusion of patients with long 
symptom durations (median: 57 months; range 5–243 months from onset), which may have 
led to right heart dilations. The accurate measurement of the RVOT diameter in adults with 
severely dilated right hearts may be difficult and impractical because the edges of the dilated 
RVOT often cannot be recognized [8], which results in substantial errors in right ventricular 
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stroke volume estimations [11]. Alternatively, using the TVILVOT and COLVOT to estimate the 
right ventricular stroke volume may be more accurate when there is neither a significant 
cardiac shunt nor aortic valvulopathy [7, 11]. Therefore, the LVOT is suitable for the 
measurement of the TVI and CO. 
Although we did not perform a validation study on a separate cohort, a post-hoc 
calculation based on the measured TRPG/COLVOT from a randomly chosen half of the patient 
group (n = 20) predicted the PVR in the remaining patients with an accuracy that was similar 
to that attained by the equation derived from the entire group (n = 20, r = 0.812, p < 0.001). 
This suggests that our equation for the PVR derived from TRPG/COLVOT could be useful for 
predicting the PVRRHC. However, a larger validation study is necessary to confirm this 
finding. 
PEA was conducted in 19 of the 40 patients, which may alter these parameters or the 
relationship with the PVRRHC. In the 19 PEA-treated patients, the mPAP and PVRRHC values 
were 25.6±7.7 mmHg and 3.9±2.0 WU, respectively, and they were not significantly lower 
than those in the entire group. The mPAP of seven PEA-treated patients was higher than 25 
mmHg despite a lapse of more than 1 year since the procedure (mPAP: 33.3±6.3 mmHg; 
PVR: 5.8±1.9 WU). Nonetheless, significant correlations between the PVRRHC and both 
TRV/COLVOT and TRPG/COLVOT were maintained, although the correlation coefficients were 
reduced compared with the whole patient sample (r = 0.470, p = 0.042; r = 0.470, p = 0.042, 
respectively). In contrast, the significant correlations between the PVRRHC and TRV/TVIRVOT, 
TRV/TVILVOT, TRPG/TVIRVOT, TRPG/TVILVOT, and TRPG/CORVOT were lost. In the non-
PEA-treated group, all of the correlations from the whole patient sample were maintained, 
except that the correlation between TRV/TVILVOT and the PVRRHC was not significant and the 
previous non-significant correlation between TRV/TVIRVOT and the PVRRHC was significant. 
However, TRPG/COLVOT remained the most strongly correlated with the PVRRHC (r = 0.774, 
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p < 0.001) (Supplementary Tables 1−4 and Supplementary Figs. 1 and 2). 
There are several limitations to this study. This was a single-center retrospective 
study that involved a small number of patients; therefore, further prospective multicenter 
studies involving larger patient populations are required to confirm the results. In addition, 
although the clinical condition of the patients was stable during each examination, the 
echocardiography and RHC were conducted 2 days apart. We only investigated patients with 
CTEPH, but TRPG/COLVOT and PVRRHC may be as strongly correlated in other conditions 
that cause PH. Thus, similar comparative analyses of echocardiographic estimations of PVR 
in other patient groups are warranted. Given that we aimed to predict PVR by 
echocardiography as a screening or follow-up tool, our study population also included 
patients treated with vasodilators and PEA. Such treatments may have influenced the 
echocardiographic parameters. Nevertheless, a significant correlation between TRPG/COLVOT 
and the PVRRHC was observed, even in postoperative patients. In future research, subgroup 
analyses will be necessary among therapy-naive and vasodilator-treated patients to assess 
possible changes in the correlation between TRPG/COLVOT and the PVRRHC. Finally, the 
echocardiography was performed by multiple examiners, so it is possible that variations 
occurred as a consequence of inter-observer differences in the measurements of the 
parameters. 
5. Conclusion 
The calculation of TRPG/COLVOT using echocardiography reliably estimates PVR, 
and it correlates strongly with direct measurements using RHC in patients with CTEPH.    
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Figure legends 
Fig. 1 – Right ventricular outflow tract (RVOT) and left ventricular outflow tract 
(LVOT) measurements in a 71-year-old male (heart rate: 65 beats/min). 
 
(A) Measurement of the RVOT time-velocity integral (TVIRVOT) by pulse Doppler tracing 
(red dotted line: 11.4 cm). The sample volume is shown in the left panel. (B) Estimation of 
RVOT diameter (red dotted line: 2.43 cm) from the parasternal short-axis view. The right 
ventricular outflow tract cardiac output (CO
RVOT
) = 11.4 × 3.14 × (2.43/2)2 × 65 = 3.4 L/min. 
(C) Measurement of the LVOT time-velocity integral (TVI
LVOT
) by pulse Doppler tracing (red 
dotted line: 17.1 cm). (D) Measurement of the LVOT diameter from the apical five-chamber 
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view (red dotted line: 1.92 cm). The LVOT cardiac output (CO
LVOT
) = 17.1 × 3.14 × (1.92/2)2
×65 = 3.2 L/min. RVOT = right ventricular outflow tract; TVILVOT = left ventricular outflow 
tract time-velocity integral; TVIRVOT = right ventricular outflow tract time-velocity integral; 
LVOT = left ventricular outflow tract. 
  
Fig. 2 – The correlation between two echo-based predictors of pulmonary vascular 
resistance (PVR) and PVR measured using right heart catheterization (PVRRHC) (n = 
40).  
 
Left: Scatter plot of the tricuspid regurgitation pressure gradient (TRPG)/cardiac output in the 
right ventricular outflow tract (CORVOT) vs. PVRRHC. Right: Scatter plot of the TRPG/cardiac 
output in the left ventricular outflow tract (COLVOT) vs. PVRRHC. The ratio of TRPG to 
COLVOT was more strongly correlated with the PVRRHC than the ratio of TRPG to CORVOT. 
PVRRHC = pulmonary vascular resistance measured by right heart catheterization; TRPG = 
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tricuspid regurgitation pressure gradient; CORVOT = cardiac output in the right ventricular 
outflow tract; COLVOT = cardiac output in the left ventricular outflow tract; WU = Wood units 
Fig. 3 – Bland-Altman analysis to evaluate the agreement between the pulmonary 
vascular resistances (PVR) derived from the tricuspid regurgitation pressure gradient 
(TRPG)/cardiac output in the left ventricular outflow tract (COLVOT) (PVRECHO) and 
PVR measured using right heart catheterization (PVRRHC).  
 
The analysis revealed a mean difference of −0.3 Wood units (WU) between the methods, with 
limits of agreement from −4.0 to 3.3 WU. PVRECHO = 1.3 + 0.3 × (TRPG/COLVOT). TRPG = 
tricuspid regurgitation pressure gradient; COLVOT = cardiac output in the left ventricular 
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outflow tract, PVRRHC = pulmonary vascular resistance measured by right heart 
catheterization; PVRECHO = pulmonary vascular resistance derived from TRPG/COLVOT; WU 
= Wood units; SD = standard deviation. 
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Supplementary Fig. 1 – The correlation between two echo-based predictors of 
pulmonary vascular resistance (PVR) and PVR measured using right heart 
catheterization (PVRRHC) in the patients who did not undergo pulmonary 
endarterectomy (n = 21). 
Left: Scatter plot of the tricuspid regurgitation pressure gradient (TRPG)/cardiac output in the 
right ventricular outflow tract (CORVOT) vs. PVRRHC. Right: Scatter plot of the TRPG/cardiac 
output in the left ventricular outflow tract (COLVOT) vs. PVRRHC. The ratio of TRPG to 
COLVOT was more strongly correlated with the PVRRHC than the ratio of TRPG to CORVOT. 
PVRRHC = pulmonary vascular resistance measured by right heart catheterization; TRPG = 
tricuspid regurgitation pressure gradient; CORVOT = cardiac output in the right ventricular 
outflow tract; COLVOT = cardiac output in the left ventricular outflow tract; WU = Wood units  
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Supplementary Fig. 2 – Bland-Altman analysis to evaluate the agreement between the 
pulmonary vascular resistances (PVR) derived from the tricuspid regurgitation 
pressure gradient (TRPG)/cardiac output in the left ventricular outflow tract (COLVOT) 
(PVRECHO) and PVR measured using right heart catheterization (PVRRHC) in the 
patients who did not undergo pulmonary endarterectomy (n = 21). 
 
The analysis revealed a mean difference of −0.3 Wood units (WU) between the methods, with 
limits of agreement from −4.0 to 3.3 WU. PVRECHO = 1.3 + 0.3 × (TRPG/COLVOT). TRPG = 
tricuspid regurgitation pressure gradient; COLVOT = cardiac output in the left ventricular 
outflow tract, PVRRHC = pulmonary vascular resistance measured by right heart 
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catheterization; PVRECHO = pulmonary vascular resistance derived from TRPG/COLVOT; WU 
= Wood units; SD = standard deviation. 
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Table 1 – Patients’ baseline clinical information (n = 40). 
Parameter  
Age (years) 62.4±11.4 
Sex, n (female/male)  30/10 
Body surface area (m
2
) 1.55±0.19 
Oxygen therapy, n  32 
Postoperative, n 19 
Vasodilators  
Prostaglandin I2, n 8 
Phosphodiesterase V inhibitors, n 8 
Endothelin antagonists, n 10 
Soluble guanylate cyclase stimulators, n 3 
The data are presented as the means±standard deviations or the numbers 
of patients. 
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Table 2 – The patients’ hemodynamic data (n = 40). 
Parameter  
PVR (Wood units) 5.4±2.9 
mPAP (mmHg) 32.1±11.4 
sPAP (mmHg) 57.7±20.9 
dPAP (mmHg) 16.0±6.8 
CO (L min-1) 4.5±1.0 
CI (L min-1 m-2) 2.9±0.5 
PAWP (mmHg) 8.4±2.9 
The data are presented as the means±standard 
deviations.  
PVR = pulmonary vascular resistance; mPAP = mean 
pulmonary arterial pressure; sPAP = pulmonary arterial 
systolic pressure; dPAP = pulmonary arterial diastolic 
pressure; CO = cardiac output; CI = cardiac index; 
PAWP = pulmonary artery wedge pressure. 
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Table 3 – Echocardiography parameters (n = 40). 
Parameter  
HR (beats/min) 67.1±10.5 
TRV (m/s) 3.4±0.7 
TRPG (mmHg) 47.4±20.8 
TVIRVOT (cm) 15.3±4.6 
TVILVOT (cm) 20.4±5.7 
CORVOT (L/min) 4.5±1.6 
COLVOT (L/min) 3.6±1.3 
TRV/TVIRVOT 0.24±0.08 
TRV/TVILVOT 0.18±0.06 
TRV/CORVOT 0.83±0.32 
TRV/COLVOT 1.04±0.41 
TRPG/TVIRVOT 3.34±1.83 
TRPG/TVILVOT 2.49±1.23 
TRPG/CORVOT 11.51±6.27 
TRPG/COLVOT 14.71±8.30 
The data are presented as the means±standard deviations.  
HR = heart rate; TRPG = tricuspid regurgitation pressure gradient; TRV = 
peak flow velocity of tricuspid regurgitation; TVIRVOT = right ventricular 
outflow tract time-velocity integral; TVILVOT = left ventricular outflow 
tract time-velocity integral; CORVOT = cardiac output in right ventricular 
outflow tract; COLVOT = cardiac output in left ventricular outflow tract. 
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Table 4. The correlations between the pulmonary vascular resistance (PVR) 
measured by right heart catheterization and the echocardiographic 
predictors of PVR (n = 40).  
Parameter Correlation (r) P value 
TRV/TVIRVOT  0.438 0.005 
TRV/TVILVOT  0.542 <0.001 
TRV/CORVOT 0.229 0.156 
TRV/COLVOT 0.704 <0.001 
TRPG/TVIRVOT 0.657 <0.001 
TRPG/TVILVOT 0.680 <0.001 
TRPG/CORVOT 0.593 0.001 
TRPG/COLVOT 0.807 <0.001 
PVRRHC = pulmonary vascular resistance measured by right heart catheterization; 
PVR = pulmonary vascular resistance; TRPG = tricuspid regurgitation pressure 
gradient; TRV = peak flow velocity of tricuspid regurgitation; TVIRVOT = right 
ventricular outflow tract time-velocity integral; TVILVOT = left ventricular 
outflow tract time-velocity integral; CORVOT = cardiac output in right ventricular 
outflow tract; COLVOT = cardiac output in left ventricular outflow tract. 
Significant correlations are shown in bold font. 
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Supplementary table 1 – Baseline clinical information of the patients 
who did not undergo pulmonary endarterectomy (n = 21). 
Parameter  
Age (years) 62.3±10.4 
Sex, n (female/male)  16/5 
Body surface area (m
2
) 1.56±0.20 
Oxygen therapy, n  20 
Postoperative, n 0 
Vasodilators  
Prostaglandin I2, n 6 
Phosphodiesterase V inhibitors, n 6 
Endothelin antagonists, n 8 
Soluble guanylate cyclase stimulators, n 3 
Data are presented as the means±standard deviations or the numbers of 
patients 
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Supplementary table 2 – Hemodynamic data of the 
patients who did not undergo pulmonary 
endarterectomy (n = 21). 
Parameter  
PVR (Wood units) 6.7±3.1 
mPAP (mmHg) 38.0±11.0 
sPAP (mmHg) 68.2±20.1 
dPAP (mmHg) 19.3±6.2 
CO (L min-1) 4.7±1.2 
CI (L min-1 m-2) 2.9±0.6 
PAWP (mmHg) 8.2±2.9 
Data are presented as the means±standard deviations. 
PVR = pulmonary vascular resistance; mPAP = mean 
pulmonary arterial pressure; sPAP = pulmonary arterial 
systolic pressure; dPAP = pulmonary arterial diastolic 
pressure; CO = cardiac output; CI = cardiac index; 
PAWP = pulmonary artery wedge pressure. 
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Supplementary table 3 – Echocardiography parameters of the 
patients who did not undergo pulmonary endarterectomy (n = 21). 
Parameter  
HR (beats/min) 65.3±11.1 
TRV (m/s) 3.7±0.7 
TRPG (mmHg) 57.1±20.2 
TVIRVOT (cm) 14.2±3.1 
TVILVOT (cm) 19.1±4.3 
CORVOT (L/min) 4.7±1.5 
COLVOT (L/min) 3.3±1.0 
TRV/TVIRVOT 0.27±0.08 
TRV/TVILVOT 0.20±0.05 
TRV/CORVOT 0.86±0.30 
TRV/COLVOT 1.21±0.41 
TRPG/TVIRVOT 4.22±2.01 
TRPG/TVILVOT 3.09±1.18 
TRPG/CORVOT 13.09±6.17 
TRPG/COLVOT 18.45±8.27 
Data are presented as the means±standard deviations. 
HR = heart rate; TRPG = tricuspid regurgitation pressure gradient; TRV 
= peak flow velocity of tricuspid regurgitation; TVIRVOT = right 
ventricular outflow tract time-velocity integral; TVILVOT = left 
ventricular outflow tract time-velocity integral; CORVOT = cardiac output 
in right ventricular outflow tract; COLVOT = cardiac output in left 
ventricular outflow tract. 
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Supplementary table 4 – The correlations between the pulmonary vascular 
resistance (PVR) measured by right heart catheterization and the 
echocardiographic predictors of PVR in the patients who did not undergo 
pulmonary endarterectomy (n = 21). 
Parameter Correlation (r) P value 
TRV/TVIRVOT  0.573 0.007 
TRV/TVILVOT  0.400 0.072 
TRV/CORVOT 0.452 0.040 
TRV/COLVOT 0.626 0.002 
TRPG/TVIRVOT 0.643 0.002 
TRPG/TVILVOT 0.584 0.005 
TRPG/CORVOT 0.610 0.003 
TRPG/COLVOT 0.774 <0.001 
TRPG = tricuspid regurgitation pressure gradient; TRV = peak flow velocity of 
tricuspid regurgitation; TVIRVOT = right ventricular outflow tract time-velocity 
integral; TVILVOT = left ventricular outflow tract time-velocity integral; CORVOT = 
cardiac output in right ventricular outflow tract; COLVOT = cardiac output in left 
ventricular outflow tract. 
Significant correlations are shown in bold font. 
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